HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alberto-Culver Q1

This article was originally published in The Rose Sheet

Executive Summary

Firm has "absolutely no intent whatsoever to consider a sale" of the consumer products business in light of the company's planned spin-off of Sally Beauty, Alberto President and CEO Howard Bernick states during first quarter sales and earnings call Jan. 26. Company recently announced it will complete sale of Sally to Regis Corporation this spring, simultaneous to Bernick's retirement (1"The Rose Sheet" Jan. 16, 2006, p. 3). In Q1, consumer product sales grew 5% to $318.9 mil., while earnings before income taxes advanced 14.7% to $31.4 mil., according to the firm. Growth of the unit was driven in part by Tresemme, which had "very strong" double-digit increases in the U.S. and Europe, firm notes. Net sales during the period were up 6% to $898.3 mil., while net earnings grew 5.4% to $52.1 mil. Firm plans to spend more than $310 mil. on advertising this year, Bernick notes...

You may also be interested in...



Alberto-Culver CEO Bernick To Retire Following Sally Spin-Off

Alberto-Culver President and CEO Howard Bernick will retire after nearly 30 years at the company following its planned spin-off of the Sally Beauty business this spring, the firm announced Jan. 10

Regulatory Measures Could Mitigate EU Coronavirus Risks

As part of its response to the coronavirus outbreak, Medicines for Europe has set out a series of policy recommendations that it says could help to mitigate the risks of COVID-19.

EU Off-Patent Industry Sees ‘Limited Immediate Risk’ From COVID-19

 The coronavirus COVID-19 outbreak poses a “limited immediate risk” to European production and supplies of off-patent drugs, according to industry association Medicines for Europe. However, if the situation continues for an extended period an “important impact” cannot be ruled out.

UsernamePublicRestriction

Register

RS013664

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel